NASDAQ: PAVM - PAVmed Inc.

Yield per half year: -39.05%
Sector: Healthcare

Share chart PAVmed Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.

More details
Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0.0005
EBITDA -0.0154
Число акций ао 0.00723 млрд
P/S 381.38
P/BV -7.49
EV/EBITDA -2.38
Цена ао 2.06
ISIN US70387R1068
Сайт https://www.pavmed.com
Валюта usd
IPO date 2016-04-28
Sector Health Care
Industry Health Care Equipment & Supplies
Валюта отчета usd
Change price per day: -1.16% (1.295)
Change price per week: +9.4% (1.17)
Change price per month: +10.34% (1.16)
Change price per 3 month: +61.15% (0.7943)
Change price per half year: -39.05% (2.1)
Change price per year: +341.38% (0.29)
Change price per 3 year: -86.09% (9.2)
Change price per 5 year: +30.61% (0.98)
Change price per year to date: +479.19% (0.221)
All parameters

Underestimation

Title Value Grade
P/S 11.68 1
P/BV -1.19 0
P/E 0 0
EV/EBITDA -0.8764 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -193.77 0
ROE, % 119.22 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.7398 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 390.4 10
Yield Ebitda, % 327.68 10
Yield EPS, % 1582.02 10
Total: 10
More

Institutions Volume Share, %
Vanguard Group Inc 302606 3.3
First Manhattan Company 200000 2.18
Blackrock Inc. 74922 0.82
Geode Capital Management, LLC 55078 0.6
Susquehanna International Group, LLP 22561 0.25
Valeo Financial Advisors, LLC 21129 0.23
State Street Corporation 20981 0.23
Northern Trust Corporation 12957 0.14
Wells Fargo & Company 11418 0.12
XML Financial, LLC 10334 0.11



Head Job title Payment Year of birth
Dr. Lishan Aklog M.D. Chairman & CEO 953.2k 1966 (58 years)
Dr. Brian J. deGuzman M.D. Executive VP, Chief Technology & Compliance Officer 427.6k 1965 (59 years)
Dr. Suman M. Verma M.D., Ph.D. Senior VP of Molecular Genetics & Chief Scientific Officer N/A
Michael Parks Vice President of Investor Relations N/A
Mr. Michael Adam Gordon Executive VP, General Counsel & Secretary 710.5k 1975 (49 years)
Dr. Deepika A. Lakhani Ph.D. Senior VP, Chief Regulatory & Quality Officer N/A
Dr. Victoria T. Lee M.D. Senior VP & Chief Medical Officer N/A
Mr. Shaun M. O'Neill M.B.A. Executive VP & COO 1982 (42 years)

Address: United States, New York. NY, 360 Madison Avenue - open in Google maps, open in Yandex maps
Website: https://www.pavmed.com